-
Alpha 1 Microglobulin ELISACatalog #: 30-6710
Sensitivity: 0.006 mg/L
Range: 0.019 - 1.5 mg/L
Sample Types: Plasma, Serum, Urine
Sample Size(s): 96 Wells
Detection: Colorimetric -
Mouse Haptoglobin ELISA
Catalog #: 41-HAPMS-E01
Sensitivity: 5 ng/mL
Range: 7.81 - 125 ng/mL
Sample Types: Plasma, Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Bovine Haptoglobin ELISA
Catalog #: 41-HAPBO-E01
Sensitivity: 15.6 ng/mL
Range: 15.6 - 1,000 ng/mL
Sample Types: Plasma, Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Equine Haptoglobin ELISA
Catalog #: 41-HAPEQ-E01
Sensitivity: 18.75 ng/mL
Range: 18.75-600 ng/mL
Sample Types: Plasma, Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Haptoglobin ELISA
Catalog #: 41-HAPHU-E01
Sensitivity: 3.125 ng/mL
Range: 3.125 - 200 ng/mL
Sample Types: Plasma, Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Alpha 2 Macroglobulin ELISA
Catalog #: 30-6610
Sensitivity: 0.05 mg/L
Range: 0.07 - 5 mg/L
Sample Types: Plasma, Serum, Stool
Sample Size(s): 96 Wells
Detection: Colorimetric -
Thymulin ELISA
Catalog #: 30-9810
Sensitivity: 0.03 ng/mL
Range: 0.03 - 16 ng/mL
Sample Types: Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Oxytocin ELISA
Catalog #: 74-OXYHU-E01
Sensitivity: 15.0 pg/mL
Range: 15.6 - 1,000 pg/mL
Sample Types: Cell Culture, Milk, Plasma, Saliva, Serum, Urine
Sample Size(s): 96 Wells
Detection: Colorimetric -
Oxytocin ELISA 5 Plate
Catalog #: 74-OXYHU-E05
Sensitivity: 15.0 pg/mL
Range: 15.6 - 1,000 pg/mL
Sample Types: Cell Culture, Milk, Plasma, Serum
Sample Size(s): 5 x 96 Wells
Detection: Colorimetric -
Follicle Stimulating Hormone ELISA (FSH ELISA)
Catalog #: 11-FSHHU-E01
Sensitivity: 1.0 IU/L
Range: 5 - 100 IU/L
Sample Types: Serum
Sample Size(s): 96 Wells
Detection: Colorimetric -
Alpha-1 Thymosin ELISA
Catalog #: 30-9510
Sensitivity: 4 ng/mL
Range: 4 - 1000 ng/mL
Sample Types: Serum, Tissue Culture
Sample Size(s): 96 Wells
Detection: Colorimetric
Responsibility
ALPCO’s Diabetes Research Travel GrantALPCO strives to provide scientists and healthcare professionals with robust tools for their research and clinical diagnostic endeavors. We understand that championing extraordinary discoveries requires extraordinary efforts, and support. We are proud to continu...
Toxicology
Drug-Induced Organ Injury
Toxicological side effects are a common obstacle in drug development pipelines and often manifest in site-specific damage to vital organs, including the liver, kidney and heart. Estimates of compound attrition from failure to meet safety endpoints are as high as 45% in pre...
New Stool-Based Gastroenterology Assays and Extraction Method Can Improve Lab Sample Processing Time By Up To 86%
Date: January 26, 2016
ALPCO recently launched a new panel of 13 stool-based gastroenterology assays that are all compatible with one single extraction step. The unique extraction method allows laboratories to improve their sample processing time by up to 86% by extracting one sample for up to 13...
Heart Disease Biomarkers in Diabetes Research
Introduction
Cardiovascular disease (CVD) encompasses a constellation of diseases related to the heart and circulatory system. Despite efforts to understand and combat CVD complications from diabetes, 65% of diabetics will pass away from cardiovascular issues1. Part 2 of The Common Denominator eBoo...
Physiological Actions of Natriuretic Peptides
Introduction
Humans have at least 50 discovered hormones managing vital biological functions in the body. These hormones are produced by the body’s organs and glands. Natriuretic peptides (NPs) are structurally related hormones synthesized and released from the heart, including atrial natriuretic p...
Stool-Based Biomarkers to Differentiate Between IBD and IBS
What are IBD and IBS?
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two different gastrointestinal tract issues affecting millions of people every day. Although there is some overlap between symptoms of IBD and IBS, differences still remain in regards to pathologies, risks...
Early Detection of Diabetic Kidney Disease with Biomarkers
Introduction
Over one third of diabetics will develop diabetic kidney disease (DKD) in their lifetime1. Despite the large amount of diabetics suffering from DKD, current methods for measuring and tracking kidney function may not be specific enough for diabetic systems2,3.
Part III of The Common ...
Emerging Biomarker Research in NAFLD and NASH
Nonalcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease in the western hemisphere affecting 1 in 3 adults and 1 in 10 children1. Today, liver biopsies are the only gold standard for precise diagnosis of NAFLD2. Because of this, there are tremendous efforts on the ...
New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week®
We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac dis...
ALPCO Announces Inaugural Young Investigators Award Recipient
October 17, 2018
ALPCO has announced the first recipient of its new young investigators award, the Diabetes Research Travel Grant. The grant was created to help advance progressive diabetes and obesity research by graduate students, postdoctoral fellows, and early stage investigators. The program...
The Relationship Between Glucagon and Energy Homeostasis
Glucagon is a gut hormone generated as a result of post translational modifications during proglucagon processing in the pancreas1,2,3. Research has demonstrated that glucagon has many physiological functions1,4. Understanding the role of glucagon in energy homeostasis has become important to many d...
Featured Biomarkers from A to Z
This handout briefly describes the role of several important hormones measured in research.